Navigation Links
Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Date:9/12/2007

B-1357 Slide Tanaka Preparation and In vitro

10:30AM Evaluation of

CDT Fluoroquinolone Prodrugs

for the Prevention and

Treatment of Osteomyelitis

Wed., 11:15AM- A-1437 Poster Van Bambeke Comparative Intracellular

Sept. 19 12:15PM Activity of 10

CDT Antistaphylococcal

Antibiotics (AABs) Against

a Stable Small Colony

Variant (SCV) of S. aureus

in a model of human THP-1

macrophages

C1-1471 Poster Arhin Mechanisms of Action of

Oritavancin in

Staphylococcus aureus

C1-1472 Poster Belley Differential Targeting of

Cell Wall Assembly Systems

by Oritavancin

C1-1473 Poster Rafai Far Cell-Wall Binding Sites of

Desleucyl (fluorophenyl)

benzylchloroeremomycin, a

Damaged Oritavancin

Analogue, in

Staphylococcus

aureus

C1-1474 Poster Wang Probing the
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Emerging technology companies receive significant funding
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. BIO 2007: Wisconsin makes its presence felt
5. TDS trades markets to gain Duluth presence
6. West Coast VC Establishes Midwest Presence in Madison
7. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
8. NameProtect releases annual list of top trademarkers
9. Doyle says new contracts saving state more than $16 million annually
10. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
11. Annual Bioethics Forum to explore genetic testing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq...ingandcommercializingnovelpainmanagementtherapies,...ExecutiveOfficer,isscheduledtopresentatthe21stAnnu...r1-2,2009atTheNewYorkPalaceHotelinNewYork,NewYork....lOfficer,willbeavailabletorespondtoquestionsduring...
(Date:11/24/2009)...Newswire/--BlueMarbleEnergyCorp.announcedtodaythat...PDA)wererecentlyawarded$2millionbyWashingtonState,...ate/publicpartnershiptoconstructthestate,sfirstspe..., "Thisinvestmentwillsignificantlyspeedthedevelo...olnCounty,"saidBlueMarbleEnergyCEOKellyOgilvie."We...
(Date:11/24/2009)...dpointhasbeenmetforpatientswithadvanced-stage,orre.../PRNewswire-FirstCall/-AEternaZentarisInc.(NASDAQ:...icalcompanyfocusedonendocrinetherapyandoncology,to...thitstargetedcytotoxicpeptideconjugate,AEZS-108(fo...ometrialcancer.Inapersonalizedhealthcareapproach,t...
(Date:11/24/2009).../PRNewswire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: ...,today,announcedthatithassubmittedaMAAtotheEuropea...enzymereplacementtherapyindevelopment,forthetreatm...pplicationforvelaglucerasealfathathasbeensubmitted...a. , Basedonaglobalsupplyshortageofthecurrent...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...Nov. 12 AMDL, Inc. (Amex:,ADL), a vertically inte...hina and the US, announced today preliminary third...ation., For the third quarter of FY2008, AMDL exp... and net sales after sales promotions of,approxima...approximately,$4.9 million and income from operati...
...Nov. 12 Novavax, Inc.,(Nasdaq: NVAX ) a clinical...ahul Singhvi, President and Chief Executive Office...s 5th Annual Healthcare Conference at 3:00 pm.,(ES...w York city. Dr.,Singhvi will provide an overview ...t progress. A link to the live presentation can be...
...alia, Nov. 12 Phosphagenics,Limited ("Phosphagenic...it,has initiated a phase 1 human clinical trial us...e targeted delivery of a leading non steroidal,ant... will compare the,bioavailability and penetration ...fenac), one of the leading marketed products, and ...
Other Biology Technology:AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 3Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans 2
(Date:11/24/2009)... Spanish . , The presence of increased body ...ubstances in the blood, hinders the loss and maint...ect of the University of Navarra conducted by Estb... Pharmacy. , The project, entitled "A nutrigenet...ol of body weight and inflammation," examines how ...
(Date:11/23/2009)... The time of day matters to forest trees dealing w...a research team led by Professor Malcolm Campbell,...l for research and colleagues in the department of.... , Capitalizing on their previous work to dec...am examined how poplar trees use their 45,000 gene...
(Date:11/23/2009)... provides "incontrovertible evidence" that the vol...tra about 73,000 years ago deforested much of cent...searchers report. , The volcano ejected an estim...re, leaving a crater (now the world,s largest volc...meters wide. Ash from the event has been found in ...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Hard To Treat Diseases 28HTDS PK 29 Thailand Registration 52304 1Hard To Treat Diseases 28HTDS PK 29 Thailand Registration 52304 2Columbia leads national effort to develop early intervention for schizophrenia 52300 1Columbia leads national effort to develop early intervention for schizophrenia 52300 2Columbia leads national effort to develop early intervention for schizophrenia 52300 3 242 million grant aids study of lung cancer in people who never smoked 9305 1 242 million grant aids study of lung cancer in people who never smoked 9305 2 242 million grant aids study of lung cancer in people who never smoked 9305 3
... , The largest living structures on Earth and the...e at risk, the most definitive review yet of the i...s concluded. , In a paper published in the presti...ientists reveal that world leaders face a race aga... communities dependent upon them for the inevitabl...
...-- A pioneering study of wild chimpanzees has foun...y experience menopause, rebutting previous studies...female chimpanzees reach reproductive senescence a...ata from wild gorillas and orangutans, the finding...logy -- suggests that human females are rare or ev...
...searchers from the University of Pennsylvania and ...ason why one of the most commonly activated protei...re Genetics this week, the Myc protein can stop th...s of nucleic acid that help control which genes ar...tances, re-introducing repressed miRNAs ,into Myc-...
Other Biology News:It's official: The carbon crisis is lethal for coral reefs 2It's official: The carbon crisis is lethal for coral reefs 3It's official: The carbon crisis is lethal for coral reefs 4Wild chimpanzees appear not to regularly experience menopause 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2
I-SAGE Ditag PCR Module* from Invitrogen
Captivate disposable sample chamber - for Captivate magnetic yoke - set of 10 from Molecular Probes (Invitrogen)
Custom Human Cytokine Antibody Array, Choose from hundreds of proteins. from Raybiotech, Inc.
I-SAGE Kit without magnetic stand from Invitrogen
Biology Products: